| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 24 | 2024 | 400 | 3.880 |
Why?
|
| Medical Oncology | 9 | 2024 | 408 | 2.110 |
Why?
|
| Electronic Health Records | 6 | 2024 | 372 | 1.760 |
Why?
|
| Neoplasms | 15 | 2024 | 3250 | 1.690 |
Why?
|
| Information Dissemination | 7 | 2024 | 126 | 1.360 |
Why?
|
| Natural Language Processing | 2 | 2023 | 42 | 1.350 |
Why?
|
| Child | 34 | 2025 | 7626 | 1.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 1178 | 1.120 |
Why?
|
| Medical Informatics | 4 | 2021 | 48 | 1.050 |
Why?
|
| Databases, Factual | 8 | 2025 | 1010 | 1.020 |
Why?
|
| Trees | 1 | 2025 | 46 | 0.900 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2015 | 416 | 0.800 |
Why?
|
| Software | 4 | 2019 | 698 | 0.780 |
Why?
|
| Pediatrics | 5 | 2024 | 399 | 0.760 |
Why?
|
| Pathology, Molecular | 2 | 2019 | 34 | 0.740 |
Why?
|
| Leukemia | 1 | 2023 | 328 | 0.680 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 491 | 0.680 |
Why?
|
| Research Report | 2 | 2021 | 43 | 0.640 |
Why?
|
| Asthma | 2 | 2025 | 1051 | 0.620 |
Why?
|
| Heuristics | 1 | 2019 | 15 | 0.610 |
Why?
|
| Humans | 69 | 2025 | 96127 | 0.610 |
Why?
|
| Rhabdomyosarcoma | 3 | 2025 | 44 | 0.610 |
Why?
|
| Radionuclide Imaging | 2 | 2021 | 217 | 0.600 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2025 | 126 | 0.570 |
Why?
|
| Child, Preschool | 16 | 2025 | 3974 | 0.550 |
Why?
|
| Biomedical Research | 3 | 2024 | 441 | 0.530 |
Why?
|
| Infant | 18 | 2025 | 3363 | 0.530 |
Why?
|
| Gene Expression Profiling | 3 | 2013 | 1534 | 0.510 |
Why?
|
| Hospital Units | 1 | 2016 | 29 | 0.510 |
Why?
|
| Emergencies | 1 | 2016 | 124 | 0.490 |
Why?
|
| Management Information Systems | 1 | 2016 | 3 | 0.490 |
Why?
|
| Patient Transfer | 1 | 2016 | 108 | 0.470 |
Why?
|
| Biomarkers, Tumor | 5 | 2022 | 1665 | 0.470 |
Why?
|
| Pressure Ulcer | 1 | 2016 | 44 | 0.460 |
Why?
|
| Adolescent | 18 | 2025 | 9896 | 0.460 |
Why?
|
| Telemedicine | 1 | 2018 | 229 | 0.460 |
Why?
|
| Polysaccharides | 1 | 2015 | 96 | 0.430 |
Why?
|
| Patient Care Team | 1 | 2016 | 307 | 0.420 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 703 | 0.410 |
Why?
|
| Paired Box Transcription Factors | 1 | 2013 | 50 | 0.400 |
Why?
|
| Critical Care | 1 | 2016 | 447 | 0.390 |
Why?
|
| Heart Arrest | 1 | 2016 | 312 | 0.390 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 3 | 2001 | 11 | 0.380 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 180 | 0.370 |
Why?
|
| Proteomics | 5 | 2016 | 269 | 0.370 |
Why?
|
| Algorithms | 4 | 2019 | 2014 | 0.370 |
Why?
|
| Oxidoreductases | 3 | 2001 | 115 | 0.360 |
Why?
|
| Lysine | 2 | 2011 | 190 | 0.360 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2022 | 58 | 0.340 |
Why?
|
| Loss of Heterozygosity | 2 | 2014 | 86 | 0.330 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2021 | 20 | 0.330 |
Why?
|
| Pharmacogenetics | 3 | 2019 | 456 | 0.320 |
Why?
|
| Patient Selection | 2 | 2024 | 709 | 0.310 |
Why?
|
| Isotope Labeling | 1 | 2009 | 53 | 0.300 |
Why?
|
| Computational Biology | 2 | 2015 | 584 | 0.300 |
Why?
|
| Databases, Protein | 1 | 2009 | 52 | 0.300 |
Why?
|
| Machine Learning | 3 | 2022 | 347 | 0.300 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 398 | 0.290 |
Why?
|
| Young Adult | 12 | 2025 | 7025 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2494 | 0.270 |
Why?
|
| N-Myc Proto-Oncogene Protein | 3 | 2017 | 40 | 0.270 |
Why?
|
| Age Factors | 4 | 2021 | 1963 | 0.270 |
Why?
|
| Patient-Centered Care | 2 | 2023 | 228 | 0.260 |
Why?
|
| Cohort Studies | 9 | 2021 | 3107 | 0.260 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 539 | 0.250 |
Why?
|
| Male | 19 | 2025 | 45870 | 0.240 |
Why?
|
| Female | 20 | 2025 | 50063 | 0.230 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2883 | 0.230 |
Why?
|
| Gene Amplification | 2 | 2017 | 143 | 0.220 |
Why?
|
| Acyl Coenzyme A | 2 | 2001 | 20 | 0.220 |
Why?
|
| Sarcoma | 2 | 2025 | 225 | 0.220 |
Why?
|
| Data Mining | 1 | 2024 | 44 | 0.220 |
Why?
|
| Hematology | 1 | 2024 | 31 | 0.210 |
Why?
|
| Prognosis | 9 | 2024 | 4033 | 0.210 |
Why?
|
| Proteins | 1 | 2009 | 816 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 247 | 0.200 |
Why?
|
| Residence Characteristics | 1 | 2025 | 213 | 0.200 |
Why?
|
| Eligibility Determination | 1 | 2023 | 38 | 0.200 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 2 | 2000 | 11 | 0.200 |
Why?
|
| Oncogene Proteins | 2 | 2015 | 65 | 0.200 |
Why?
|
| Hodgkin Disease | 1 | 2024 | 170 | 0.200 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 2059 | 0.200 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 1763 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 639 | 0.190 |
Why?
|
| Disease Progression | 2 | 2025 | 1568 | 0.190 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 6 | 0.190 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 49 | 0.190 |
Why?
|
| Chromatography, Liquid | 2 | 2015 | 104 | 0.180 |
Why?
|
| Chicago | 2 | 2025 | 1503 | 0.180 |
Why?
|
| Mutation | 4 | 2015 | 4374 | 0.180 |
Why?
|
| Genomics | 4 | 2022 | 855 | 0.180 |
Why?
|
| Data Collection | 2 | 2023 | 381 | 0.180 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2794 | 0.170 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 123 | 0.170 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 354 | 0.170 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 108 | 0.170 |
Why?
|
| Arginine | 1 | 2001 | 144 | 0.170 |
Why?
|
| User-Computer Interface | 2 | 2019 | 194 | 0.170 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 2081 | 0.170 |
Why?
|
| Substrate Specificity | 1 | 2001 | 368 | 0.170 |
Why?
|
| Survivorship | 1 | 2020 | 20 | 0.160 |
Why?
|
| Adult | 11 | 2025 | 28718 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 25 | 0.160 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 38 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1469 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 123 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 701 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 2642 | 0.150 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 9 | 0.150 |
Why?
|
| Workflow | 1 | 2019 | 80 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 750 | 0.150 |
Why?
|
| Biomedical Technology | 1 | 2018 | 26 | 0.140 |
Why?
|
| Research | 1 | 2020 | 265 | 0.140 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 107 | 0.140 |
Why?
|
| Survivors | 2 | 2016 | 204 | 0.140 |
Why?
|
| Smartphone | 1 | 2018 | 54 | 0.140 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 36 | 0.140 |
Why?
|
| Risk Factors | 8 | 2024 | 5960 | 0.140 |
Why?
|
| Database Management Systems | 1 | 2018 | 44 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 204 | 0.130 |
Why?
|
| Coronary Care Units | 1 | 2016 | 5 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 568 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2021 | 1546 | 0.130 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2016 | 39 | 0.120 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 7 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 155 | 0.120 |
Why?
|
| Caspase 10 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Melphalan | 1 | 2016 | 100 | 0.120 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 69 | 0.120 |
Why?
|
| Mitochondria | 1 | 2000 | 623 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 151 | 0.120 |
Why?
|
| Hydrazines | 1 | 2015 | 33 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 81 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 138 | 0.120 |
Why?
|
| Physician's Role | 1 | 2017 | 186 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 763 | 0.110 |
Why?
|
| Carbohydrate Sequence | 1 | 2015 | 21 | 0.110 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 25 | 0.110 |
Why?
|
| Proteome | 1 | 2016 | 156 | 0.110 |
Why?
|
| Triazoles | 1 | 2015 | 110 | 0.110 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 193 | 0.110 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2014 | 7 | 0.110 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 3041 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2016 | 713 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 2473 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2016 | 327 | 0.110 |
Why?
|
| Glycosylation | 1 | 2015 | 137 | 0.110 |
Why?
|
| Exome | 1 | 2015 | 141 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 244 | 0.110 |
Why?
|
| Registries | 1 | 2020 | 986 | 0.110 |
Why?
|
| Skull | 1 | 2016 | 273 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2015 | 195 | 0.110 |
Why?
|
| Plasma Cells | 1 | 2015 | 88 | 0.110 |
Why?
|
| Anticoagulants | 2 | 2019 | 463 | 0.110 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 46 | 0.110 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 24 | 0.110 |
Why?
|
| Protein Conformation | 2 | 2011 | 935 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2022 | 2480 | 0.110 |
Why?
|
| DNA Repair | 2 | 2016 | 376 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2014 | 118 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 156 | 0.100 |
Why?
|
| Critical Illness | 1 | 2016 | 346 | 0.100 |
Why?
|
| Infant, Newborn | 4 | 2024 | 2614 | 0.100 |
Why?
|
| Neurocalcin | 1 | 2013 | 2 | 0.100 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2013 | 29 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2016 | 361 | 0.100 |
Why?
|
| Inpatients | 1 | 2016 | 347 | 0.100 |
Why?
|
| Sex Factors | 1 | 2016 | 1133 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2014 | 163 | 0.100 |
Why?
|
| Citric Acid | 1 | 2013 | 48 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 908 | 0.100 |
Why?
|
| Cell Separation | 1 | 2013 | 205 | 0.100 |
Why?
|
| Isovaleryl-CoA Dehydrogenase | 3 | 2001 | 3 | 0.090 |
Why?
|
| DNA Damage | 1 | 2014 | 392 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2014 | 328 | 0.090 |
Why?
|
| Heparin | 1 | 2013 | 187 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 944 | 0.090 |
Why?
|
| Enzyme Stability | 3 | 2001 | 41 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 381 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1351 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 2012 | 45 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2014 | 301 | 0.090 |
Why?
|
| Acetylation | 1 | 2011 | 149 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2014 | 463 | 0.090 |
Why?
|
| Middle Aged | 4 | 2019 | 28363 | 0.090 |
Why?
|
| Ubiquitin | 1 | 2011 | 95 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 7232 | 0.090 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 342 | 0.080 |
Why?
|
| Gene Expression | 1 | 2015 | 1322 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 1195 | 0.080 |
Why?
|
| Methylation | 1 | 2011 | 295 | 0.080 |
Why?
|
| Time Factors | 2 | 2016 | 5585 | 0.080 |
Why?
|
| Survival Rate | 3 | 2024 | 1986 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2014 | 565 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 841 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1773 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 750 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2011 | 518 | 0.080 |
Why?
|
| Precision Medicine | 3 | 2021 | 451 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 855 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 828 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 563 | 0.080 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 75 | 0.080 |
Why?
|
| Apoptosis | 1 | 2015 | 1763 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 107 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2009 | 50 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2009 | 66 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2011 | 1157 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 102 | 0.070 |
Why?
|
| Isoantibodies | 1 | 2010 | 127 | 0.070 |
Why?
|
| Cell Line | 2 | 2013 | 2533 | 0.070 |
Why?
|
| Ecosystem | 2 | 2023 | 394 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2010 | 281 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2009 | 127 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 206 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 272 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2009 | 154 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 2422 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2022 | 4671 | 0.070 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 150 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 393 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 1103 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2009 | 477 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 156 | 0.060 |
Why?
|
| Aged | 3 | 2019 | 20964 | 0.060 |
Why?
|
| Models, Molecular | 2 | 2001 | 1375 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1083 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2016 | 318 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2013 | 1730 | 0.060 |
Why?
|
| Mice | 3 | 2016 | 12562 | 0.060 |
Why?
|
| Models, Biological | 1 | 2011 | 1815 | 0.050 |
Why?
|
| Genotype | 1 | 2009 | 1882 | 0.050 |
Why?
|
| Health Information Interoperability | 1 | 2024 | 7 | 0.050 |
Why?
|
| Protein Binding | 2 | 2013 | 1561 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 631 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 72 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3927 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10286 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 1034 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 137 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 74 | 0.050 |
Why?
|
| Africa | 1 | 2022 | 107 | 0.050 |
Why?
|
| Energy Transfer | 1 | 2001 | 26 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 85 | 0.040 |
Why?
|
| Incidence | 2 | 2016 | 1715 | 0.040 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 336 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2020 | 22 | 0.040 |
Why?
|
| Hemiterpenes | 1 | 2000 | 6 | 0.040 |
Why?
|
| Pentanoic Acids | 1 | 2000 | 6 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 370 | 0.040 |
Why?
|
| Animals | 4 | 2016 | 28945 | 0.040 |
Why?
|
| Leucine | 1 | 2000 | 62 | 0.040 |
Why?
|
| Mitosis | 1 | 2020 | 159 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 404 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 305 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 124 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 422 | 0.040 |
Why?
|
| Biological Transport | 1 | 2000 | 412 | 0.040 |
Why?
|
| United States | 2 | 2023 | 7767 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 901 | 0.040 |
Why?
|
| Warfarin | 1 | 2019 | 107 | 0.040 |
Why?
|
| Binding Sites | 1 | 2001 | 1167 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 404 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 9173 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2017 | 42 | 0.030 |
Why?
|
| Durapatite | 1 | 2016 | 36 | 0.030 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 6 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2092 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 88 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 35 | 0.030 |
Why?
|
| Glutathione | 1 | 2016 | 107 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2015 | 38 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2015 | 54 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 703 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 161 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 880 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 301 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 79 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 134 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2015 | 55 | 0.030 |
Why?
|
| Bortezomib | 1 | 2015 | 82 | 0.030 |
Why?
|
| Thalidomide | 1 | 2015 | 56 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1054 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 135 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2014 | 61 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 344 | 0.030 |
Why?
|
| Pyrazines | 1 | 2015 | 94 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 16 | 0.030 |
Why?
|
| Computer Security | 1 | 2014 | 17 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 692 | 0.030 |
Why?
|
| Information Systems | 1 | 2014 | 30 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2015 | 304 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 197 | 0.030 |
Why?
|
| Confidentiality | 1 | 2014 | 79 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 535 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 177 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 1933 | 0.030 |
Why?
|
| SEER Program | 1 | 2014 | 235 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 53 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2015 | 351 | 0.020 |
Why?
|
| Internet | 1 | 2015 | 339 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1958 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 377 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2013 | 288 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 303 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 514 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 554 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 706 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 623 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1275 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1807 | 0.020 |
Why?
|
| Laryngeal Edema | 1 | 2010 | 7 | 0.020 |
Why?
|
| Hemagglutinins | 1 | 2010 | 22 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 992 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2010 | 42 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 793 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 672 | 0.020 |
Why?
|
| Acute Chest Syndrome | 1 | 2010 | 24 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 165 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 304 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2010 | 203 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 1205 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2551 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1666 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 873 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1619 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 2010 | 346 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 3147 | 0.010 |
Why?
|
| Mitochondria, Liver | 1 | 1998 | 29 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1998 | 108 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 395 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1998 | 527 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1998 | 547 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 1562 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 1267 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1998 | 627 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1998 | 781 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 2943 | 0.010 |
Why?
|
| Rats | 1 | 1998 | 4154 | 0.010 |
Why?
|